Drug profile · INN
nintedanib ethanesulfonate
OFEV INITIAL APPROVAL
nintedanib ethanesulfonate (OFEV INITIAL APPROVAL) is a fibroblast growth factor receptor inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — nintedanib ethanesulfonate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
nintedanib ethanesulfonate (OFEV INITIAL APPROVAL) is a fibroblast growth factor receptor inhibitor.
Key facts
INN nintedanib ethanesulfonate
Brand OFEV INITIAL APPROVAL
Mechanism Fibroblast growth factor receptor inhibitor
Target Fibroblast growth factor receptor
Mechanism of action
Fibroblast growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nintedanib ethanesulfonate?
nintedanib ethanesulfonate (OFEV INITIAL APPROVAL) is a fibroblast growth factor receptor inhibitor.
What is the brand name for nintedanib ethanesulfonate?
OFEV INITIAL APPROVAL is a marketed brand name for nintedanib ethanesulfonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.